Glenmark initiates multi-country Phase 3 clinical trial for Envafolimab in resectable Stage III NSCLC

The company has received approval from DCGI to begin patient enrolment and dosing in the country

Cupid’s B2B export order book stands at Rs. 100 Cr+

These orders are from international government tenders in South Africa, Tanzania, and Kenya, as well as from international agencies WHO/UNFPA, NGOs like MSI and PSI

FDA approves Lecanemab autoinjector, marking first at-home treatment for Alzheimer disease

The new subcutaneous autoinjector for lecanemab offers a self-administered, at-home treatment option for early-stage Alzheimer's disease

Roche, Alnylam to initiate Phase 3 cardiovascular outcomes trial of zilebesiran

Zilebesiran, a potential best-in-disease RNAi anti-hypertensive with twice-yearly subcutaneous dosing, demonstrated encouraging safety when combined with two or more antihypertensives

FDA approved Dawnzera in US as first and only RNA-targeted prophylactic treatment for hereditary angioedema

Dawnzera demonstrated significant and sustained HAE attack rate reduction and long-term disease control

FDA approves first immunotherapy for recurrent respiratory papillomatosis

Enable injections receives enFuse system approval in Brazil and UK registration

Asian Institute of Nephrology & Urology expands hospital in Banjara Hills, Hyderabad

AINU is set to accelerate its expansion footprint, enhance operational capabilities

Biocon Biologics expands diabetes portfolio with FDA approval of Kirsty

Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx